Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Disease Areas › Cancer › Blood-Based Gene Expression Signature May ID Prostate Cancer Patients' Response to Hormonal Drugs

Blood-Based Gene Expression Signature May ID Prostate Cancer Patients' Response to Hormonal Drugs

Oct 05, 2020
|
staff reporter

NEW YORK – Using baseline blood samples, a group of researchers have identified a gene expression signature that may predict which patients with metastatic castration-resistant prostate cancer (CRPC) are most likely to respond to treatment with the antiandrogen agents abiraterone (Janssen's Zytiga) plus prednisone (AAP) or enzalutamide (Pfizer/Astellas' Xtandi).

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Feb
11
Featured Webinar

Virtual Molecular Tumor Board Series: HRD and DNA Damage Repair

Sponsored by
Foundation Medicine

In this session, the first in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified biomarkers related to homologous recombination deficiency and DNA damage repair.

Feb
22
Featured Webinar

Trends in Variant Interpretation Workflows: Expert Insights to Advance NGS Oncology Profiling

Sponsored by
Qiagen

Please join GenomeWeb and Qiagen for an online roundtable discussion where a panel of experts will review challenges and opportunities around genomic variant interpretation workflows in the field of oncology.

Feb
25
Featured Webinar

Virtual Molecular Tumor Board Series: Common Driver Mutations in ‘Off-Label’ Tumor Types

Sponsored by
Foundation Medicine

In this session, the second in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review cases in which patient genomic profiles exhibit common driver mutations in tumor types considered “off label” for targeted therapies associated with those mutations.

Mar
11
Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

What's Popular?

In Cancer

  1. MacroGenics' Margenza Improves PFS Over Herceptin in Phase III Breast Cancer Trial

  2. Caris Shares Data for AI-Driven Tumor Origin Prediction, Hinting at Diagnostic, Patient Benefit

    Premium

  3. MMRF, Dana Farber Amassing Data to Develop Smoldering Multiple Myeloma Monitoring Test

    Premium

  4. Exelixis Initiates Phase I Study of Anti-CDK7 Agent in Solid Tumors

  5. Henry Ford Health System Opens New Cancer Pavilion With Precision Medicine Focus

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.